Oppenheimer Initiates Coverage On Catalyst Pharmaceuticals with Outperform Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has initiated coverage on Catalyst Pharmaceuticals with an Outperform rating and set a price target of $30. The company is listed on NASDAQ under the ticker CPRX.
December 21, 2023 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals received an Outperform rating from Oppenheimer with a price target of $30, indicating a positive outlook from the analyst.
The initiation of coverage by Oppenheimer with an Outperform rating and a high price target typically generates positive investor sentiment and can lead to a short-term increase in the stock price due to heightened expectations.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100